Michael R Grunwald MDChief, Leukemia Division, Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina
Dr. Grunwald is Chief of the Leukemia Division and Associate Professor at Levine Cancer Institute of Atrium Health. He cares for patients with acute and chronic leukemias, including myelodysplastic syndromes and myeloproliferative neoplasms. He also cares for patients receiving cellular therapy, including blood and marrow transplants. He is an active clinical investigator, leading trials for leukemia and transplant patients. He participates in studies with the Blood and Marrow Transplant Clinical Trials Network and the Center for International Blood and Marrow Transplant Research. He is a member of the American Society of Hematology, American Society of Clinical Oncology, American Society for Transplant and Cellular Therapy, American Medical Association, and American College of Physicians.
Dr. Grunwald has consulted for Abbvie, Alexion, Amgen, Ariad, Astellas, BMS/Celgene, Cardinal Health, Daiichi Sankyo, Merck, Pfizer, Premier, and Trovagene. Dr. Grunwald has received research funding from Amgen, Forma Therapeutics, Genentech/Roche, Incyte, Janssen, and Novartis.